white-logo HW250117 16th World ADC San Diego Summit logo W
OCTOBER 12 - 15 2026 | SAN DIEGO, CALIFORNIA

World ADC San Diego 2026

SCHEDULE A MEETING
Hero BG WorldADC25 (1) (1)
event icon

Bioanalytical Strategies for ADC Development
From discovery through clinical analysis, BioAgilytix delivers integrated bioanalytical strategies for antibody-drug conjugates (ADCs), helping sponsors generate reliable data to understand their therapeutic and support confident development decisions.

Event Overview

World ADC San Diego brings together scientists and drug developers advancing antibody-drug conjugates across discovery, preclinical development, translational research, clinical development, and manufacturing.

The meeting provides a forum for sharing scientific advances, addressing development challenges, and exploring new approaches across the rapidly evolving ADC landscape.

San Diego-1

Details

noun-calendar-5687483 1 1
October 12-15, 2026
noun-location-5687484 1 1
Booth #108
Town and Country San Diego
San Diego, California

Featured Scientific Poster

Ben Nie Headshot

Presented by Ben Nie, PhD

BioAgilytix

Title

Leveraging LC/MS as the Preferred Pharmacokinetic Platform for Dual Payload Antibody-Drug Conjugates


Presentation date and time to be announced.
Visit Booth #108 to discuss the poster and connect with our scientific team during the conference.

G63A3365

Supporting Complex ADC Bioanalysis

ADCs combine multiple components into a single therapeutic, creating bioanalytical questions that can require more than one analytical approach.
Understanding exposure, immunogenicity, biomarkers, and other critical endpoints requires an analytical strategy designed around the molecule, study objectives, and stage of development

Meet with our experts to discuss:

  • ADC Bioanalysis

  • Pharmacokinetics

  • Ligand Binding Assays

  • LC-MS

  • Immunogenicity

  • Biomarkers

  • Method Development & Validation

  • Preclinical & Clinical Bioanalysis 

Why ADC Sponsors Partner with BioAgilytix
ADC programs require analytical strategies capable of addressing the complexity of the therapeutic while generating reliable data throughout development. Our scientists work alongside sponsors to develop fit-for-purpose approaches aligned with the molecule, study objectives, and development stage.

Integrated Analytical Technologies
Our teams bring together complementary technologies, including ligand binding assays and LC-MS, to develop bioanalytical strategies tailored to complex ADC programs.

Scientific Expertise Across Development
From preclinical studies through clinical development, our scientists help sponsors determine appropriate analytical approaches for pharmacokinetics, immunogenicity, biomarkers, and other program-specific bioanalytical endpoints.

Global Development Support
With harmonized laboratories across North America, Europe, and Australia, BioAgilytix supports global development programs with consistent scientific quality and regulatory-ready data.

Questions We Can Help Answer

What makes bioanalysis for ADCs different from traditional biologics?

ADCs combine an antibody with a conjugated payload, creating additional analytical complexity and potentially multiple analytes of interest. The appropriate bioanalytical strategy depends on the ADC design, development stage, study objectives, and scientific questions the program needs to answer.

What analytical technologies can be used to support ADC bioanalysis?

Depending on the molecule and study objectives, ADC programs may use ligand binding assays, LC-MS, or complementary analytical approaches. BioAgilytix works with sponsors to select fit-for-purpose technologies based on the analyte, matrix, required sensitivity, and intended use of the data.

Can BioAgilytix support both ligand binding assays and LC-MS for ADC programs?

Yes. BioAgilytix has expertise across both ligand binding assays and LC-MS, allowing our scientists to develop complementary analytical strategies when appropriate for the ADC and development program.

How does BioAgilytix support pharmacokinetic assessment for ADCs?

Pharmacokinetic strategies for ADCs require measurement of different analytes depending on the therapeutic and study objectives. Our scientists work with sponsors to determine appropriate assay strategies and analytical platforms, including LBA and LC-MS approaches, to generate reliable PK data.

When should immunogenicity be considered in an ADC development program?

Immunogenicity strategy should be considered as part of the broader bioanalytical plan and aligned with the therapeutic, development stage, and regulatory expectations. BioAgilytix supports the development and validation of immunogenicity assays designed around program-specific requirements.

Can biomarker strategies be incorporated into ADC development?

Yes. Biomarker strategies can provide additional insight into pharmacodynamic response, safety, efficacy, and biological activity. Our teams work with sponsors to align biomarker strategy with the scientific objectives and stage of the development program.

Can BioAgilytix support ADC programs across preclinical and clinical development?

Yes. BioAgilytix supports bioanalytical programs from preclinical development through clinical studies, allowing analytical strategies to evolve alongside the program while maintaining scientific and data continuity.

Schedule a Meeting

Build the Right Bioanalytical Strategy for Your ADC Program
    
Whether you're advancing an ADC through preclinical development, preparing for clinical studies, or refining an existing bioanalytical strategy, our scientists are ready to discuss approaches tailored to your molecule and development goals.

Visit Booth #108 or schedule a meeting with our team to learn how BioAgilytix can support your ADC development program with reliable, regulatory-ready bioanalytical data
 

© Copyright 2026 BioAgilytix Labs. All rights reserved.

Privacy Policy

Terms Of Use

icon-linkedin-footer youtube-footer